Skip to main content

Table 3 Interruption characteristics by age group

From: Elderly patients with atrial fibrillation in routine clinical practice—peri-procedural management of edoxaban oral anticoagulation therapy is associated with a low risk of bleeding and thromboembolic complications: a subset analysis of the prospective, observational, multinational EMIT-AF study

Age (years)

N

No interruption

1 day interruption

 ≥ 2 days interruption

Pre-procedural interuption duration

 < 65

279

145 (52.0%)

54 (19.4%)

80 (28.7%)

 ≥ 65

1161

422 (36.3%)

320 (27.6%)

419 (36.1%)

 < 75

828

365 (44.1%)

206 (24.9%)

257 (31.0%)

 ≥ 75

612

202 (33.0%)

168 (27.5%)

242 (39.5%)

 ≥ 65– < 75

549

220 (40.1%)

152 (27.7%)

177 (32.2%)

 ≥ 75– < 85

514

178 (34.6%)

138 (26.8%)

198 (38.5%)

 ≥ 85

98

24 (24.5%)

30 (30.6%)

44 (44.9%)

Post-procedural interuption duration

 < 65

279

226 (81.0%)

19 (6.8%)

34 (12.2%)

 ≥ 65

1157

810 (70.0%)

93 (8.0%)

254 (22.0%)

 < 75

825

621 (75.3%)

56 (6.8%)

148 (17.9%)

 ≥ 75

611

415 (67.9%)

56 (9.2%)

140 (22.9%)

 ≥ 65– < 75

546

395 (72.3%)

37 (6.8%)

114 (20.9%)

 ≥ 75– < 85

514

351 (68.3%)

50 (9.7%)

113 (22.0%)

 ≥ 85

97

64 (66.0%)

6 (6.2%)

27 (27.8%)

Interuption incidence

 < 65

279

134 (48.0%)

92 (33.0%)

11 (3.9%)

65–74

549

194 (35.3%)

201 (36.6%)

26 (4.7%)

75–84

514

158 (30.7%)

193 (37.5%)

20 (3.9%)

 ≥ 85

98

21 (21.4%)

43 (43.9%)

3 (3.1%)

 ≥ 65

1161

373 (32.1%)

437 (37.6%)

49 (4.2%)

 < 75

828

328 (39.6%)

293 (35.4%)

37 (4.5%)

 ≥ 75

612

179 (29.2%)

236 (38.6%)

23 (3.8%)